Novartis AG (NVS)
160.65
-4.50
(-2.72%)
USD |
NYSE |
Mar 05, 15:49
Novartis Cash from Investing (Quarterly) : -2.111B for Dec. 31, 2025
Cash from Investing (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
Cash From Investing Definition
Cash from Investing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall investing activities of the company. A few examples of investing activities include net change in PP&E, and net divestitures.
Cash from Investing (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Investing (Quarterly) Benchmarks
| Roche Holding AG | -- |
| Amgen, Inc. | -693.00M |
| AstraZeneca PLC | -1.501B |
| Gilead Sciences, Inc. | -1.835B |
| GSK Plc | -3.184B |
Cash from Investing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | 2.254B |
| Cash from Financing (Quarterly) | 1.713B |
| Free Cash Flow | 15.32B |
| Free Cash Flow Per Share (Quarterly) | 0.6409 |
| Free Cash Flow to Equity (Quarterly) | -2.118B |
| Free Cash Flow to Firm (Quarterly) | 1.463B |
| Free Cash Flow Yield | 4.89% |